Glycoprotein VI As a Prognostic Biomarker for Cardiovascular Death in Patients with Symptomatic Coronary Artery Disease

Overview

Journal Clin Res Cardiol

Specialty Cardiology & Vascular Diseases

Date 2010 Jan 6

PMID 20049463

Citations 4

Authors

Boris Bigalke

Konstantinos Stellos

Tobias Geisler

Stephan Lindemann

Andreas E May

Meinrad Gawaz

Affiliations

Soon will be listed here.

Abstract

Background: Platelets play a critical role in arterial thrombosis, acute coronary syndrome (ACS) and stroke. Platelet collagen receptor glycoprotein VI (GPVI) is associated with acute coronary events and a poor clinical outcome.

Methods: Between January 2006 and March 2009, we evaluated 2,213 consecutive patients in a prospective study design, who presented with chest pain. Among 1,819 patients (82.2%) who underwent coronary angiography, 1,652 patients (90.8%) showed a coronary and 167 patients (9.2%) a non-coronary origin of chest pain. 901 patients (54.5%) presented with an ACS, 751 (45.5%) with a stable angina pectoris. Clinical outcome was performed by a predefined structured telephone interview after a 3-month follow-up (92.8%:1,533 of 1,652 patients).

Results: Kaplan-Meier analysis for cumulative event-free survival revealed that patients with a elevated baseline GPVI expression had a poorer clinical outcome for cardiovascular death than patients with decreased GPVI levels (log rank; P = 0.040). These results were paralleled in composite cumulative survival that included myocardial infarction, stroke, and cardiovascular death (log rank; P = 0.002). Relative risk of cardiovascular death was found at 1.41 (95% CI 1.08-1.85) for platelet GPVI, 1.64 (95% CI 1.31-2.05) for brain natriuretic peptide, 1.16 (95% CI 0.81-1.64) for troponin-I and 1.33 (95% CI 0.97-1.82) for C-reactive protein.

Conclusions: Patients with CAD presenting increased levels of platelet GPVI had a poorer outcome and may profit from a dual antiplatelet therapy. Thus, GPVI may be a useful prognostic tool for adverse cardiovascular events. Future studies should substantiate GPVI for its potential role of risk prediction and consider its prognostic value to improve risk stratification.

Citing Articles

Emerging Factors Implicated in Fibrotic Organ-Associated Thrombosis: The Case of Two Organs.

Leiva O, Bekendam R, Garcia B, Thompson C, Cantor A, Chitalia V TH Open. 2019; 3(2):e165-e170.

PMID: 31259299 PMC: 6598088. DOI: 10.1055/s-0039-1692204.

Prenatal lead exposure is associated with decreased cord blood DNA methylation of the glycoprotein VI gene involved in platelet activation and thrombus formation.

Engstrom K, Rydbeck F, Kippler M, Wojdacz T, Arifeen S, Vahter M Environ Epigenet. 2018; 1(1):dvv007.

PMID: 29492281 PMC: 5804686. DOI: 10.1093/eep/dvv007.

Targeting GPVI as a novel antithrombotic strategy.

Andrews R, Arthur J, Gardiner E J Blood Med. 2014; 5:59-68.

PMID: 24899824 PMC: 4039396. DOI: 10.2147/JBM.S39220.

Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.

Povsic T, Sullenger B, Zelenkofske S, Rusconi C, Becker R J Cardiovasc Transl Res. 2010; 3(6):704-16.

PMID: 21080135 DOI: 10.1007/s12265-010-9230-6.

References

Bigalke B, Geisler T, Stellos K, Langer H, Daub K, Kremmer E . Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome. Am Heart J. 2008; 156(1):193-200. DOI: 10.1016/j.ahj.2008.02.010. View

Al-Tamimi M, Mu F, Moroi M, Gardiner E, Berndt M, Andrews R . Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets. 2009; 20(3):143-9. DOI: 10.1080/09537100802710286. View

Bhatt D, Fox K, Hacke W, Berger P, Black H, Boden W . Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354(16):1706-17. DOI: 10.1056/NEJMoa060989. View

Kisucka J, Chauhan A, Zhao B, Patten I, Yesilaltay A, Krieger M . Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood. 2009; 113(23):6015-22. PMC: 2700332. DOI: 10.1182/blood-2008-10-186650. View

Morrow D, Sabatine M, Brennan M, de Lemos J, Murphy S, Ruff C . Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J. 2008; 29(9):1096-102. PMC: 2829435. DOI: 10.1093/eurheartj/ehn071. View

Geisler T, Kapp M, Gohring-Frischholz K, Daub K, Dosch C, Bigalke B . Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart. 2007; 94(6):743-7. DOI: 10.1136/hrt.2006.100891. View

Kurz K, Schild C, Isfort P, Katus H, Giannitsis E . Serial and single time-point measurements of cardiac troponin T for prediction of clinical outcomes in patients with acute ST-segment elevation myocardial infarction. Clin Res Cardiol. 2008; 98(2):94-100. DOI: 10.1007/s00392-008-0727-9. View

James S, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P . N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded.... Circulation. 2003; 108(3):275-81. DOI: 10.1161/01.CIR.0000079170.10579.DC. View

Anderson J, Adams C, Antman E, Bridges C, Califf R, Casey Jr D . ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to.... Circulation. 2007; 116(7):e148-304. DOI: 10.1161/CIRCULATIONAHA.107.181940. View

10.

Mockel M, Muller R, Vollert J, Muller C, Danne O, Gareis R . Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol. 2007; 96(9):604-12. DOI: 10.1007/s00392-007-0540-x. View

11.

Bigalke B, Lindemann S, Ehlers R, Seizer P, Daub K, Langer H . Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J. 2006; 27(18):2165-9. DOI: 10.1093/eurheartj/ehl192. View

12.

Ndrepepa G, Braun S, Mehilli J, Niemoller K, Schomig A, Kastrati A . A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes. Clin Res Cardiol. 2006; 96(1):30-7. DOI: 10.1007/s00392-006-0457-9. View

13.

Brugger-Andersen T, Aarsetoy H, Grundt H, Staines H, Nilsen D . The long-term prognostic value of multiple biomarkers following a myocardial infarction. Thromb Res. 2008; 123(1):60-6. DOI: 10.1016/j.thromres.2008.01.012. View

14.

Sanchis J, Bosch X, Bodi V, Bellera N, Nunez J, Benito B . Combination of clinical risk profile, early exercise testing and circulating biomarkers for evaluation of patients with acute chest pain without ST-segment deviation or troponin elevation. Heart. 2007; 94(3):311-5. DOI: 10.1136/hrt.2007.115626. View

15.

Sabatine M, Morrow D, de Lemos J, Gibson C, Murphy S, Rifai N . Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002; 105(15):1760-3. DOI: 10.1161/01.cir.0000015464.18023.0a. View

16.

Debrunner M, Schuiki E, Minder E, Straumann E, Naegeli B, Mury R . Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol. 2008; 97(5):298-305. DOI: 10.1007/s00392-007-0626-5. View

17.

Tousoulis D, Kampoli A, Stefanadi E, Antoniades C, Siasos G, Papavassiliou A . New biochemical markers in acute coronary syndromes. Curr Med Chem. 2008; 15(13):1288-96. DOI: 10.2174/092986708784534965. View

18.

Bigalke B, Stellos K, Geisler T, Kremmer E, Seizer P, May A . Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke. Eur J Neurol. 2009; 17(1):111-7. DOI: 10.1111/j.1468-1331.2009.02754.x. View

19.

Tschoepe D, Schultheiss H, KOLAROV P, Schwippert B, Dannehl K, Nieuwenhuis H . Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation. 1993; 88(1):37-42. DOI: 10.1161/01.cir.88.1.37. View

20.

Chung I, Choudhury A, Patel J, Lip G . Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure. Ann Med. 2008; 41(1):45-51. DOI: 10.1080/07853890802227089. View